The bladder cancer market has remained largely unchanged in the past 10-20 years. However, significant expansion is expected starting in 2016, with the introduction of several new therapies that are projected to fuel market growth. In addition, bladder cancer has a robust early-stage pipeline that will contribute to market growth beyond the forecast period of 2012-2017. Currently, the bladder cancer market is dominated by generic chemotherapy and immunotherapy.
Though initially effective, toxicity and lack of clinical efficacy in improving overall survival have left the door open for more tolerable and effective drugs to be developed. In the past, bladder cancer has not been an area of focus for pharmaceutical companies, but that is rapidly changing as more companies focus on the bladder cancer market, recognizing the high level of unmet need and relatively clear regulatory path. During the forecast period, the market landscape will begin to change dramatically with the introduction of targeted immunotherapies. These drugs will provide much-needed alternatives to bladder cancer patients who have not benefitted from traditional treatments.
To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=547962
– Overview of bladder cancer, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
– Annualized bladder cancer therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2012 and forecast for 5 years to 2017.
– Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the bladder cancer therapeutics market.
– Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
– Analysis of the current and future market competition in the global bladder cancer therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Table of Contents
1 Table of Contents1.1 List of Tables
1.2 List of Figures
2.2 Related Reports
2.3 Upcoming Related Reports
3 Disease Overview
3.1 Etiology and Pathophysiology
3.1.3 Clinical Staging
3.3 Quality of Life
4.1 Disease Background
4.2 Risk Factors and Co-morbidities
4.2.1 Smoking is the most significant risk factor for bladder cancer
4.2.2 Up to 25% of male bladder cancer cases are due to occupational exposure to aromatic amines
4.3 Global and Historical Trends
4.3.1 Incidence, Mortality, and Five-Year Prevalence
4.3.2 Relative Survival
4.3.3 Disability-Adjusted Life Years and Years of Life Lost
4.4 Forecast methodology
4.4.1 Sources used
4.4.2 Forecast assumptions and methods
4.4.3 Sources not used
4.5 Incident/Prevalent Cases of Bladder Cancer
4.5.1 Incident Cases of Bladder Cancer
4.5.2 Age-Specific Incident Cases of Bladder Cancer
4.5.3 Sex-Specific Incident Cases of Bladder Cancer
4.5.4 Age-Standardized Incidence Rates of Bladder Cancer
4.5.5 Incident Cases of Bladder Cancer by Stage at Diagnosis
4.5.6 Five-Year Prevalent Cases of Bladder Cancer
4.6.1 Epidemiological Forecast Insight
4.6.2 Limitations of the Analysis
4.6.3 Strengths of the Analysis
5 Current Treatment Options
5.2 Product Profiles- Major Brands
5.2.1 Intravesical Bacillus Calmette-Guerin
5.2.2 GemCis (Gemcitabine/Cisplatin)
5.2.3 Mitomycin c
5.2.4 Valstar (Valrubicin)
5.2.5 Javlor (Vinfluinine Ditartrate)
Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=547962